Transforming Time-to-Market with Smarter Formulation Data Analysis and Revvity Signals

By streamlining formulation research processes, pharmaceutical generics and biosimilars companies can cut time-to-market, and seize a greater market share for their therapies.

For pharmaceutical generics and biosimilars companies, every possible technique that can cut development time and reduce costs is clearly at an immense premium, yet the formulation process is often plagued with workflow bottlenecks, manual processes, and a lack of data integration.
 

The Challenges of Manual Processes
 

Modern R&D produces vast libraries of highly complex data. Scientists find themselves managing and analyzingexperimental data across multiple formulations, with multiple teams contributing as each formulation makes its way through analytical and stability tests. Often, each unit relies on its own systems and processes to store results in varying formats, in isolated systems.
 

Data scattered across the organization creates digital friction, with manual processes needed to find and collate information prior to analysis, leading to slower decision-making. In addition, in this scenario, collecting compliance documentation for candidate drugs can be a particularly laborious and time-consuming process.
 

Transforming Formulation Data Analysis with RevvitySignals
 

Here at Revvity Signals, we are continually innovating with our digital platforms to support efficient formulation R&D processes. By using Revvity Signals software, formulation departments can move away from tedious manual processes and focus on high-value research and analysis. With experimental data sorted into the data-tables within Signals Notebook, from Revvity Signals, formulation scientists can embrace self-help analytics, comparing different datasets effortlessly and creating custom views to simplify data visualization, achieving near-real-time insights for informed decision-making.
 

Additionally, Signals Notebook enables automation for formulation departments. With enhanced calculation functionalities automatically resolving even the most complex calculations, scientists can achieve higher efficiency and improve accuracy. Furthermore, with AI-driven predictive analytics, scientists can use copilots and agents to securely and instantly access relevant data. By leveraging AI tools toforecast formulation stability and performance, using natural language queries, teams can further streamline the R&D process and cut down on the time and costs associated with repeated formulation experiments.
 

Digital Tools for Faster Drug Development
 

By deploying an integrated, advanced digital platform such asSignals Notebook, from Revvity Signals, to collect data across departments, pharma companies can introduce more-structured data management, increase collaboration, and boost productivity by freeing scientists from manual data entry.
 

In a recent example, Hyderabad-based Natco Pharma selected Signals Notebook to transition to digital workflows, therebyenhancing the development process and accelerating filings for regulatory approvals. Automation and integratedworkflows help Natco Pharma to reduce R&D timescales, cut the risk of human error, and ensure data accuracy and relevancy.
 

The Future of Formulations Research
 

As pharma companies look to cut costs and reduce the time-to-market, new tools continuously emerge to support formulation data analysis, including AI. Effective AI relies on creating and curating trustworthy source datasets, with suitable guardrails. With a unified data strategy, based on the Revvity Signals solutions, companies can reap the benefits of embedded AI capabilities, safely and securely.
 

With smarter, faster and more efficient formulation R&D powered by Revvity Signals software solutions, pharmaceutical companies can reduce operational costs, cut time-to-market, and stay ahead of the competition.